Reprogramming of somatic cells

Patent metadata

Field	Value
Publication number	US-9714414-B2
Application number	US-201414473250-A
Country	US
Kind code	B2
Filing date	Aug 29, 2014
Priority date	Apr 7, 2007
Publication date	Jul 25, 2017
Grant date	Jul 25, 2017

Abstract

The disclosure relates to a method of reprogramming one or more somatic cells, e.g., partially differentiated or fully/terminally differentiated somatic cells, to a less differentiated state, e.g., a pluripotent or multipotent state. In further embodiments the invention also relates to reprogrammed somatic cells produced by methods of the invention, to uses of said cells, and to methods for identifying agents useful for reprogramming somatic cells.

First claim

What is claimed is:

1. A method of reprogramming a cell to a pluripotent state comprising: (a) introducing into the cell exogenous factors comprising (i) polynucleotides encoding Oct-4, Sox-2, and Klf-4, but not c-Myc; or (ii) Oct-4, Sox-2, and Klf-4 polypeptides, but not a c-Myc polypeptide, and (b) culturing the cell for a sufficient amount of time to reprogram the cell to the pluripotent state, wherein the reprogrammed cell does not express a selectable marker operably linked to a pluripotency gene.

2. The method of claim 1 , wherein the polynucleotides are introduced by transfection or viral infection.

3. The method of claim 1 , wherein step (a) comprises introducing said polynucleotides into the cell; and the method further comprising inactivating at least one of the polynucleotides after the cell obtains the pluripotent state, wherein said inactivating optionally comprises excising at least a portion of a coding sequence from the at least one of the polynucleotides, wherein the portion of the coding sequence is flanked by sequences that are recognized by a site-specific recombinase, and wherein said excising comprises introducing or expressing the site-specific recombinase in the cell after the cell obtains the pluripotent state, wherein the site-specific recombinase removes the portion of the coding sequence from the at least one of the polynucleotides.

4. A method of reprogramming a human adult somatic cell to a pluripotent state comprising the steps of: (a) introducing into a human adult somatic cell reprogramming agents that contribute to reprogramming of the cell, wherein the reprogramming agents comprise Oct-4, Sox-2, and Klf-4, but not c-Myc; and (b) culturing the cell in a medium comprising cell proliferation factors and factors that support reprogramming for a period of time sufficient to reprogram the cell to the pluripotent state, wherein the cell does not comprise a selectable marker operably linked to an endogenous pluripotency gene.

5. The method of claim 4 , wherein the reprogramming agents are introduced as (i) polynucleotides encoding Oct-4, Sox-2, and Klf-4, but not c-Myc; or (ii) Oct-4, Sox-2, and Klf-4 polypeptides, but not a c-Myc polypeptide.

6. The method of claim 4 , wherein the somatic cell is a partially differentiated cell or a fully differentiated cell.

7. A method of generating a reprogrammed human pluripotent cell comprising: introducing into a human somatic cell, exogenous polynucleotides encoding Oct-4, Sox-2, and Klf-4, but not c-Myc; or exogenous Oct-4, Sox-2, and Klf-4 polypeptides, but not a c-Myc polypeptide, culturing said human somatic cell for a sufficient amount of time to obtain a reprogrammed human pluripotent that (i) is resistant to DNA demethylation; (ii) expresses endogenous Oct-4; (iii) differentiates into tissues having the characteristics of endoderm, mesoderm, and ectoderm when injected into SCID mice; and (iv) does not comprise a selectable marker operably linked to an endogenous pluripotency gene.

8. The method of claim 7 , wherein the exogenously introduced polynucleotides are introduced into the human somatic cell by transfection or viral infection.

9. The method of claim 7 , wherein step (a) comprises introducing said polynucleotides into the human somatic cell; and the method further comprising inactivating at least one of the polynucleotides after the human somatic cell becomes the reprogrammed human pluripotent cell, wherein said inactivating optionally comprises excising at least a portion of a coding sequence from the at least one of the polynucleotides, wherein the portion of the coding sequence is flanked by sequences that are recognized by a site-specific recombinase, and wherein said excising comprises introducing or expressing the site-specific recombinase in the cell after the human somatic cell becomes the reprogrammed human pluripotent cell, wherein the site-specific recombinase removes the portion of the coding sequence from the at least one of the polynucleotides.

Assignees

• Whitehead Inst Biomedical Res

Inventors

• Jaenisch Rudolf
• Hanna Yaqub
• Wernig Marius
• Lengner Christopher J
• Meissner Alexander
• Brambrink Oliver Tobias
• Welstead G Grant
• Foreman Ruth

Classifications

• A61P5/14

  of the thyroid hormones, e.g. T3, T4 · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P5/18

  of the parathyroid hormones · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P5/00

  Drugs for disorders of the endocrine system · CPC title